One step closer to a new drug for multiple myeloma in Europe24 Aug 2015
The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.
On July 23, ixazomib was granted accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA, a designation reserved for those medicines deemed to be of major public health interest and, in particular, therapeutic innovation.
New treatment option for adult multiple myeloma patients
The MAA submission was primarily based on the results of the first pre-specified interim analysis of the pivotal Phase 3 trial. The TOURMALINE-MM1 trial is an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.
Patients continue to be treated to progression in this trial and will be evaluated for long-term outcomes.
In addition to the ixazomib MAA submission with the EMA, a New Drug Application for ixazomib was filed with the US Food and Drug Administration (FDA). Additional filings in other countries are planned to begin later this fiscal year.
Source: eCancer News